(Q33812021)

29 July 2017

1 reference

title

Treatment of proliferative diabetic retinopathy with anti-VEGF agents (English)

1 reference

proliferative diabetic retinopathy

29 July 2017

1 reference

1 reference

Aysha Salam

1

1 reference

29 July 2017

Raeba Mathew

series ordinal

2

1 reference

29 July 2017

Sobha Sivaprasad

series ordinal

3

1 reference

29 July 2017

language of work or name

1 reference

5 February 2011

1 reference

29 July 2017

1 reference

29 July 2017

89

1 reference

29 July 2017

5

1 reference

29 July 2017

405-411

1 reference

Anti-VEGF therapy in proliferative diabetic retinopathy.

29 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Retinal pigment epithelial tear after intravitreal ranibizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Bevacizumab as adjuvant for neovascular glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Alterations in the intraocular cytokine milieu after intravitreal bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Review of anti-VEGF therapy in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Progression of tractional retinal detachment following intravitreal bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

The prevalence of diabetic retinopathy among adults in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Bevacizumab and retinal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

VEGF function in vascular pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Systemic adverse events after bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Complications in patients after intravitreal injection of bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

FIBROUS MEMBRANES IN DIABETIC RETINOPATHY AND BEVACIZUMAB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02079.X

10.1111/J.1755-3768.2010.02079.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference